United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the company's stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $561.50, for a total transaction of $5,615,000.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,598,874. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Edgemond also recently made the following trade(s):
- On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $593.17, for a total transaction of $5,931,700.00.
- On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00.
- On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00.
United Therapeutics Stock Performance
United Therapeutics stock opened at $559.65 on Tuesday. The firm has a market cap of $24.53 billion, a P/E ratio of 20.06, a P/E/G ratio of 1.63 and a beta of 0.75. The business's fifty day moving average is $508.43 and its two-hundred day moving average is $480.83. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $607.89.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business's revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.19 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Institutional Trading of United Therapeutics
Hedge funds have recently modified their holdings of the stock. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB boosted its stake in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after acquiring an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in United Therapeutics in the fourth quarter valued at approximately $48,000. 94.08% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of research firms have commented on UTHR. Jefferies Financial Group reissued a "buy" rating on shares of United Therapeutics in a research note on Monday, March 2nd. Bank of America increased their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a research note on Tuesday, March 31st. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. Weiss Ratings reissued a "buy (b)" rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Wells Fargo & Company increased their price target on shares of United Therapeutics from $486.00 to $575.00 and gave the company an "equal weight" rating in a research note on Tuesday, March 31st. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $586.00.
Read Our Latest Stock Analysis on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
